The present invention concerns methods for treating multiple sclerosis (MS) in a patient by using the anti-CD20 antibody ocrelizumab, and an article of manufacture with instructions for such use. In particular it relates to a dosage regimen of ocrelizumab wherein the initial and second dose is of 1,2 grams for patients of less than 75 kg weight or of 1,8 grams for patients of 75 kg or more at an interval of about 6 months.
METHODS FOR TREATING MULTIPLE SCLEROSIS WITH OCRELIZUMAB